Polfa Sa Tarchomin

What Polfa Sa Tarchomin does

TZF Polfa is a Polish pharmaceutical manufacturer headquartered in Warsaw and the oldest pharmaceutical company in Poland, founded in 1823. It operates as an S.A. (Spółka Akcyjna) with registered capital of PLN 184,913,610 and an employee base of 5,001–10,000. The company produces over 50 products in 130 forms and doses spanning prescription drugs (Rx) — including antibiotics, human insulins, dermatological, and CNS medications — alongside over-the-counter (OTC) products, dietary supplements, dermocosmetics, and the PolhuminPen insulin injector. It also manufactures active pharmaceutical ingredients (APIs).

The company's core technology platform centers on a modern OEB 5 high-potency drug production line — one of the most advanced in Central-Eastern Europe — coupled with 12,000+ m² of production space including 3,000 m² of cleanrooms class C and higher. In October 2025, TZF Polfa unveiled a new High-Potency Drug Development and Production Center for injectable products, and in 2025 launched a dedicated OEB 5 parenteral laboratory conducting over 4,000 tests annually. Operations comply with cGMP standards for EU, FDA, and EAEU markets, and the company is responsible for producing 10% of the EU critical medicines list.

TZF Polfa monetizes through three revenue streams: contract manufacturing (CMO/CDMO) of APIs and finished dosage forms for pharmaceutical clients, direct B2B sales of proprietary and manufactured products to hospitals, pharmacies, and medical facilities (delivering 25 million packages annually worldwide), and laboratory services covering preformulation and analytical testing. Go-to-market is enterprise-direct via hospital procurement systems and pharmaceutical distribution networks, with quote-based pricing. The customer base spans public and private hospitals, retail and hospital pharmacies, and pharmaceutical companies seeking CMO/CDMO capacity, particularly for high-potency injectable and sterile parenteral products.

Name

Polfa Sa Tarchomin

Legal name

Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.

Website

https://polfa-tarchomin.com.pl

Company type

Private

Founded year

1823

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

TZF Polfa is a Polish pharmaceutical manufacturer and contract manufacturer (CMO/CDMO) founded in 1823, producing 50+ prescription and OTC products, APIs, and sterile injectable drugs for hospitals, pharmacies, and pharmaceutical companies worldwide.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Pharmaceutical manufacturing
• Contract manufacturing services
• Active pharmaceutical ingredients
• Prescription medications
• Sterile injectable products

Headquarters

HQ city

Warszawa

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Infrastructure, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing (CMO/CDMO): Revenue from contract manufacturing of active pharmaceutical ingredients (API) and finished dosage forms (FDF) for pharmaceutical companies. Services include preformulation, analytical support, and production of high-potency drugs and parenteral products.
2. Pharmaceutical Product Sales: Revenue from sale of proprietary and manufactured pharmaceutical products including prescription drugs (Rx), over-the-counter (OTC) products, dietary supplements, and dermocosmetics. Distribution to hospitals, pharmacies, and medical facilities.
3. Laboratory Services: Revenue from laboratory services including preformulation studies, analytical testing (over 4,000 tests annually), and quality control for pharmaceutical products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

TZF Polfa manufactures and supplies a portfolio of over 50 pharmaceutical products in 130 forms and dosages, including prescription drugs (antibiotics, human insulins, dermatological and CNS drugs), OTC products, dietary supplements, dermocosmetics, and active pharmaceutical ingredients (APIs). The company also provides contract manufacturing (CMO/CDMO) services for API and finished dosage forms with one of Central-Eastern Europe's most modern OEB 5 high-potency drug production lines, along with preformulation and analytical laboratory services.

Product overview

TZF Polfa is a pharmaceutical company offering a portfolio of over 50 products in 130 forms and doses. The core offerings include prescription medications (Rx) such as antibiotics, human insulins, dermatological drugs, and CNS medications; over-the-counter products (OTC); dietary supplements; and dermocosmetics. The company also manufactures active pharmaceutical ingredients (APIs) and PolhuminPen injectors. Supporting the product portfolio are contract manufacturing services (CMO/CDMO) with one of the most modern high-potency drug (OEB 5) production lines in Central-Eastern Europe, and laboratory services including preformulation and analytical support with over 4000 annual tests. The company delivers 25 million packages annually to hospitals, pharmacies, and medical facilities, and is responsible for 10% of the EU critical medicines list production.

Differentiator

Problem solved

Functional benefit

Products and services

• Prescription Medications (Rx)

Quantifiable outcome

• Production of 10% of EU critical medicines list
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• KRKA: Slovenian-led generic pharmaceutical manufacturer with a strong CEE, Central Asian, and Eastern European footprint. Closely comparable in scale, finished-dose generics focus, and multi-region manufacturing footprint.
• Polpharma: Poland's largest pharmaceutical manufacturer and TZF Polfa's most direct domestic competitor. Operates a comparable generic Rx portfolio, FDF manufacturing, and contract services across CEE, with similar hospital and pharmacy distribution channels.
• Hikma Pharmaceuticals: UK-listed generic and specialty pharmaceutical company with a leading injectables franchise. Directly comparable to TZF Polfa's sterile parenteral and high-potency injectable manufacturing focus, including CMO/CDMO relationships with hospital customers.
• Recipharm: European CDMO providing contract development and manufacturing services for APIs and finished dosage forms. Directly comparable to TZF Polfa's CMO/CDMO service line, including high-potency and sterile fill-finish capabilities for pharma clients.
• Gedeon Richter: Hungarian pharmaceutical group combining branded originator and generic drug manufacturing with significant European and CIS-market reach. Overlaps with TZF Polfa in generics, women's health, and CEE/CIS distribution channels.
• Zentiva: One of Europe's largest generic pharmaceutical manufacturers, headquartered in the Czech Republic with deep CEE roots. Targets the same hospital, pharmacy, and tender procurement channels as TZF Polfa with overlapping therapeutic-area coverage in generics.

Emerging players

• Alvotech: Icelandic biosimilars developer and manufacturer focused on sterile injectable biologics. Partial overlap with TZF Polfa's parenteral and high-potency manufacturing, but specialised in biosimilars rather than small-molecule generics.

Broad incumbents

• Sandoz: Recently spun off from Novartis as the world's largest standalone generics and biosimilars company. Competes with TZF Polfa in generic Rx and biosimilars-adjacent injectables, but from a much larger platform with global commercial reach.
• Stada Arzneimittel: German-headquartered European generic and specialty pharmaceutical company with strong retail-pharmacy and CEE distribution. Comparable in generic FDF product breadth and European CDMO positioning to TZF Polfa.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with global API and FDF operations. A broader incumbent player in the same product categories as TZF Polfa, but at vastly greater scale and with much broader therapeutic and geographic reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/polfa-tarchomin
• Xx.com/TZFPolfa

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polfa Sa Tarchomin